Telomere-homologous G-rich oligonucleotides sensitize human ovarian cancer cells to TRAIL-induced growth inhibition and apoptosis

Nucleic Acid Therapeutics

Volumn 23, Issue 3, 2013, Pages 167-174

  Sarkar, Sibaji ^a   Faller, Douglas V ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 7; CASPASE 9; DEATH RECEPTOR 4; DEATH RECEPTOR 5; OLIGONUCLEOTIDE; TELOMERE HOMOLOGOUS G RICH OLIGONUCLEOTIDE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; MITOCHONDRIAL PERMEABILITY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TELOMERE; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASE 3; CASPASE 7; CASPASE 8; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SYNERGISM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAP KINASE KINASE 4; OLIGONUCLEOTIDES; OVARIAN NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; TELOMERE; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84878225462     PISSN: 21593337     EISSN: None     Source Type: Journal    
DOI: 10.1089/nat.2012.0401     Document Type: Article

References (24)

1. BAE, S.I., CHERIYATH, V., JACOBS, B.S., REU, F.J., and BORDEN, E.C. (2008). Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL. Oncogene 27, 490-498.
2. CAMIDGE, D.R. (2008). Apomab: an agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumors. Expert Opin. Biol. Ther. 8, 1167-1176.
3. CHAWLA-SARKAR, M., BAE, S.I., REU, F.J., JACOBS, B.S., LINDNER, D.J., and BORDEN, E.C. (2004). Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced ap-optosis. Cell Death Differ. 11, 915-923.
4. CUMMINS, J.M., KOHLI, M., RAGO, C., KINZLER, K.W., VOGELSTEIN, B., ND BUNZ, F. (2004). X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells. Cancer Res. 64, 3006-3008.
5. DUIKER, E.W., DE VRIES, E.G., MAHALINGAM, D., MEERS-MA, G.J., BOERSMA-VAN, EK W., HOLLEMA, H., LUB-DE HOOGE, M.N., VAN DAM, G.M., COOL, R.H., QUAX, W.J. et al. (2009). Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model. Clin. Cancer Res. 15, 2048-2057.
6. ESTES, J.M., OLIVER, P.G., STRAUGHN, J.M., JR., ZHOU, T., WANG, W., GRIZZLE, W.E., ALVAREZ, R.D., STOCKARD, C.R., LOBUGLIO, A.F., and BUCHSBAUM, D.J. (2007). Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model. Gynecol. Oncol. 105, 291-298.
7. HIETAKANGAS, V., POUKKULA, M., HEISKANEN, K.M., KARVINEN, J.T., SISTONEN, L., and ERIKSSON, J.E. (2003). Erythroid differentiation sensitizes K562 leukemia cells to TRAIL-induced apoptosis by downregulation of c-FLIP. Mol. Cell Biol. 23, 1278-1291.
8. HORAK, P., PILS, D., HALLER, G., PRIBILL, I., ROESSLER, M., TOMEK, S., HORVAT, R., ZEILLINGER, R., ZIELINSKI, C., and KRAINER, M. (2005). Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer. Mol. Cancer Res. 3, 335-343.
9. HOTTE, S.J., HIRTE, H.W., CHEN, E.X., SIU, L.L., LE, L.H., COREY, A., IACOBUCCI, A., MACLEAN, M., LO, L., FOX, N.L. et al. (2008). A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin. Cancer Res. 14, 3450-3455.
10. IGNEY, F.H., and KRAMMER, P.H. (2002). Death and anti-death: tumour resistance to apoptosis. Nat. Rev. Cancer 2, 277-288.
11. LANE, D., ROBERT, V., GRONDIN, R., RANCOURT, C., and PICHE, A. (2007). Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells. Int. J. Cancer 121, 1227-1237.
12. LIU, J., and MATULONIS, U.A. (2010). New advances in ovarian cancer. Oncology (Williston Park) 24, 721-728.
13. LONGE, H.O., ROMESSER, P.B., RANKIN, A.M., FALLER, D.V., ELLER, M.S., GILCHREST, B.A., and DENIS, G.V. (2009). Telomere homolog oligonucleotides induce apoptosis in malignant but not in normal lymphoid cells: mechanism and therapeutic potential. Int. J. Cancer 124, 473-482.
14. PARK, S. J., KIM, M. J., KIM, H. B., SOHN, H. Y., BAE, J. H., KANG, C. D., and KIM, S. H. (2009). TrichostatinA sensitizes human ovarian cancer cells to TRAIL induced apoptosis by down regulation of C-FLIPL via inhibition of EGFR pathway. Biochem. Pharmacol. 77, 1328-1336.
15. PITTI, R.M., MARSTERS, S.A., RUPPERT, S., DONAHUE, C.J., MOORE, A., and ASHKENAZI, A. (1996). Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271, 12687-12690.
16. PURI, N., ELLER, M.S., BYERS, H.R., DYKSTRA, S., KUBERA, J., and GILCHREST, B.A. (2004). Telomere-based DNA damage responses: a new approach to melanoma. FASEB J 18, 1373-1381.
17. RANKIN, A.M., SARKAR, S., and FALLER, D.V. (2011). Mechanism of T-oligo-induced cell cycle arrest in Mia-PaCa pancreatic cancer cells. J. Cell Physiol. 227, 2586-2594.
18. SARKAR, S., and FALLER, D.V. (2011). T-oligos inhibit growth and induce apoptosis in human ovarian cancer cells. Oligo-nucleotides 21, 47-53.
19. TOMEK, S., HORAK, P., PRIBILL, I., HALLER, G., ROSSLER, M., ZIELINSKI, C.C., PILS, D., and KRAINER, M. (2004). Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs. Gy-necol. Oncol. 94, 107-114.
20. VIGANTI, S., CODEQONI, A., POLETO, F., and BRUQQUINI, M. (2002). TRAIL activity in human ovarian cancer cells. European J. Cancer 38, 177-183.
21. WILEY, S.R., SCHOOLEY, K., SMOLAK, P.J., DIN, W.S., HUANG, C.P., NICHOLL, J.K., SUTHERLAND, G.R., SMITH, T.D., RAUCH, C., SMITH, C.A. et al. (1995). Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3, 673-682.
22. YAAR, M., ELLER, M.S., PANOVA, I., KUBERA, J., WEE, L.H., COWAN, K.H., and GILCHREST, B.A. (2007). Telomeric DNA induces apoptosis and senescence of human breast carcinoma cells. Breast Cancer Res. 9, R13.
23. ZHANG, S., BALCH, C., CHAN, M.W., LAI, H.C., MATEI, D., SCHILDER, J.M., YAN, P.S., HUANG, T.H., and NEPHEW, K.P. (2008). Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 68, 4311-4320.
24. ZHAO, E., ZHOU, M., FU, C., SHEN, B., ZHANG, Q., and LIAN, L. (1995). Effects of TNF alone or in combination with chemotherapeutic agents on human ovarian cancers in vitro and in nude mice. Chin. Med. J. (Engl.) 108, 571-575.